Skip to main content
. 2016 Jan 12;6(1):e711. doi: 10.1038/tp.2015.191

Figure 3.

Figure 3

Increased levels of 5MC and 5HMC on Gad1 (a) and Reln (b) promoter regions in the frontal cortex of PRS mice are reduced by treatment with clozapine (CLZ) but not haloperidol (HAL). Note there is no enrichment of 5MC or 5HMC on Gad2 (c) promoter region in the PRS and NS mice. Dose and schedule of drug treatment are as described in Figure 1. Data are expressed as mean±s.e.m. and analyzed with one-way ANOVA followed by Student–Newman–Keuls multiple comparisons. ANOVA for Gad1 5MC (F5,41=5.8, P<0.001), Gad1 5HMC (F5,42=5.8, P<0.001); Reln 5MC (F5,37=5.4, P<0.001), Reln 5HMC (F5,42=5.8, P<0.001); Gad2 5MC (F5,42=0.64, P=0.2), Gad2 5HMC (F5,42=1,49, P=0.24). *P<0.05 when vehicle (VEH)-treated PRS samples are compared with PRS clozapine-treated samples or with treated or untreated NS samples. #P<0.05 when haloperidol-treated PRS samples are compared with PRS clozapine-treated samples or with treated and untreated NS samples. ANOVA, analysis of variance; 5HMC, 5-hydroxymethylcytosine; 5MC, 5-methylcytosine; NS, nonstressed; PRS, prenatally stressed.